Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study
- 29 September 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical and Experimental Nephrology
- Vol. 10 (3), 193-200
- https://doi.org/10.1007/s10157-006-0427-6
Abstract
The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study has previously shown losartan to confer significant benefits to patients with type 2 diabetes and nephropathy. The original study of 1513 patients included 96 Japanese patients; the present study is a post-hoc analysis of the effects of losartan in this Japanese subpopulation.Keywords
This publication has 38 references indexed in Scilit:
- Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAALKidney International, 2006
- Losartan reduces the costs of diabetic end‐stage renal disease: An Asian perspectiveNephrology, 2005
- Renoprotection with and without blood pressure reductionKidney International, 2005
- An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) StudyDiabetologia, 2004
- Treatment of type 2 diabetic patients with kidney disease with AT 1 -receptor antagonists: lessons from recent trialsClinical and Experimental Nephrology, 2002
- The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)Journal of the Renin-Angiotensin-Aldosterone System, 2000
- Pharmacoepidemiology of ACE Inhibitor???Induced CoughDrug Safety, 1997
- Abnormal Albuminuria as a Predictor of Mortality and Renal Impairment in Chinese Patients With NIDDMDiabetes Care, 1995
- Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertensionThe American Journal of Cardiology, 1995
- Predicting Diabetic Nephropathy in Insulin-Dependent PatientsNew England Journal of Medicine, 1984